Lexaria Announces Exercises of Existing Warrants

Lexaria Bioscience Corp. (CSE:LXX,OTCQB:LXRP) (the “Company” or “Lexaria”) announces various option and warrant transactions.
Lexaria announces it has received US$95,857.20from the exercise of a stock warrants and a compensation option certificate previously granted. The compensation option certificate was exercised at the price of US$0.42 and a total of 7,200 common shares are being issued. This exercise is by a third party who is neither an officer nor a director of the Company. The Company has also received for exercise a total of 230,062 warrants previously granted; being 9,000 @ US$0.14; 125,400 @ US$0.273; and 95,662 @ US$0.60.
No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH^TM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Click here to connect with Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) for an Investor Presentation.

Source: www.accesswire.com